Market research
DMTK DermTech Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- 2.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US24984K1051
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- 2.42
About
About DermTech Inc
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DMTK discussion.
5 years, 4 months ago
DermTech, Inc is currently in a long term downtrend where the price is trading 7.2% below its 200 day moving average.
From a valuation standpoint, the stock is 88.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 149.4.
DermTech, Inc's total revenue rose by 33.5% to $2M since the same quarter in the previous year.
Its net income has dropped by 84.6% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.3% to $-7M since the same quarter in the previous year.
Based on the above factors, DermTech, Inc gets an overall score of 2/5.